Director of Health Economics Outcomes Research
ArineFull Time
Expert & Leadership (9+ years)
Amylyx is a clinical-stage pharmaceutical company based in Cambridge, Massachusetts, with an audacious mission to develop novel therapies for high unmet needs. We are currently focused on post-bariatric hypoglycemia (PBH), Wolfram syndrome, progressive supranuclear palsy (PSP), and amyotrophic lateral sclerosis (ALS). Where others see challenges, we see opportunities that we pursue with urgency, rigorous science, and unwavering commitment to the communities we serve.
Our mission is powered by our people. Our core values – be audacious, be curious, be authentic, be engaged, and be accountable – create a culture of caring. Amylyx has assembled an experienced team ready to take action because the communities we serve have no time to wait. If you share our passion and determination, we encourage you to read the opportunity below and apply.
The Senior Director, Health Economics and Outcomes Research (HEOR)/Real World Evidence (RWE) at Amylyx Pharmaceuticals will report to the SVP of Medical Affairs. This position will be an expert and experienced leader, engaging cross functionally to develop and drive HEOR and evidence generation strategies. The Senior Director will play an integral role in developing and communicating the value proposition for Amylyx’ assets, including our lead program in post-bariatric hypoglycemia (PBH). This role will drive development of strategies, methods, and tools to ensure successful market access, adoption, and long-term impact in support of Amylyx’ mission to find solutions for patients with high unmet needs.
Develops treatments for neurodegenerative diseases
Amylyx Pharmaceuticals develops treatments for neurodegenerative diseases, focusing on conditions like Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease (ALZ). Their main product, AMX0035, is currently undergoing clinical trials to assess its effectiveness. The CENTAUR ALS trial showed promising results for ALS patients, using a randomized, double-blind, placebo-controlled design to ensure reliable outcomes. They are also conducting the PEGASUS trial to evaluate AMX0035's safety and effectiveness in Alzheimer's patients. Unlike many competitors, Amylyx emphasizes community engagement and awareness campaigns, such as ALS Awareness Month, to educate the public and foster support for those affected by these diseases. The company's goal is to bring effective therapies to market that improve patient outcomes and enhance the quality of life for individuals suffering from neurodegenerative conditions.